Schizophrenia Research
Volume 118, Issue 1 , Pages 98-105 , May 2010

A reappraisal of the association between Dysbindin (DTNBP1) and schizophrenia in a large combined case–control and family-based sample of German ancestry

  • Jana Strohmaier

      Affiliations

    • Division of Genetic Epidemiology, Central Institute of Mental Health, Mannheim, Germany
    • ,
  • Josef Frank

      Affiliations

    • Division of Genetic Epidemiology, Central Institute of Mental Health, Mannheim, Germany
    • ,
  • Jens R. Wendland

      Affiliations

    • Unit on the Genetic Basis of Mood and Anxiety Disorders, NIMH, NIH, Bethesda, USA
    • ,
  • Johannes Schumacher

      Affiliations

    • Unit on the Genetic Basis of Mood and Anxiety Disorders, NIMH, NIH, Bethesda, USA
    • Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany
    • ,
  • Rami Abou Jamra

      Affiliations

    • Institute of Human Genetics, University of Bonn, Bonn, Germany
    • ,
  • Jens Treutlein

      Affiliations

    • Division of Genetic Epidemiology, Central Institute of Mental Health, Mannheim, Germany
    • ,
  • Vanessa Nieratschker

      Affiliations

    • Division of Genetic Epidemiology, Central Institute of Mental Health, Mannheim, Germany
    • ,
  • René Breuer

      Affiliations

    • Division of Genetic Epidemiology, Central Institute of Mental Health, Mannheim, Germany
    • ,
  • Manuel Mattheisen

      Affiliations

    • Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany
    • Institute of Human Genetics, University of Bonn, Bonn, Germany
    • ,
  • Stefan Herms

      Affiliations

    • Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany
    • Institute of Human Genetics, University of Bonn, Bonn, Germany
    • ,
  • Thomas W. Mühleisen

      Affiliations

    • Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany
    • Institute of Human Genetics, University of Bonn, Bonn, Germany
    • ,
  • Wolfgang Maier

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
    • ,
  • Markus M. Nöthen

      Affiliations

    • Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany
    • Institute of Human Genetics, University of Bonn, Bonn, Germany
    • ,
  • Sven Cichon

      Affiliations

    • Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany
    • Institute of Human Genetics, University of Bonn, Bonn, Germany
    • ,
  • Marcella Rietschel

      Affiliations

    • Division of Genetic Epidemiology, Central Institute of Mental Health, Mannheim, Germany
    • ,
  • Thomas G. Schulze

      Affiliations

    • Division of Genetic Epidemiology, Central Institute of Mental Health, Mannheim, Germany
    • Unit on the Genetic Basis of Mood and Anxiety Disorders, NIMH, NIH, Bethesda, USA
    • Corresponding Author InformationCorresponding author. Unit on the Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health (NIMH), National Institutes of Health (NIH), 35 Convent Drive, Bldg. 35, Rm 1A205, MSC 3719, Bethesda, MD 20892-3719, USA. Tel.: +1 301 451 7213; fax: +1 301 402 9081.

Received 19 August 2009 ,Revised 8 December 2009 ,Accepted 20 December 2009.

References 

  1. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–265
  2. Bowie CR, Harvey PD. Administration and interpretation of the Trail Making Test. Nat. Protoc. 2006;1(5):2277–2281
  3. Bray NJ, Preece A, Williams NM, Moskvina V, Buckland PR, Owen MJ, et al. Haplotypes at the destrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum. Mol. Genet. 2005;14(14):1947–1954
  4. Bray NJ, Holmans PA, van den Bree MB, Jones L, Elliston LA, Hughes G, et al. Cis- and trans- loci influence expression of the schizophrenia susceptibility gene DTNBP1. Hum. Mol. Genet. 2008;17(8):1169–1174
  5. Brekke JS, Hoe M, Long J, Green MF. How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr. Bull. 2007;33(5):1247–1256
  6. Buckholtz JW, Sust S, Tan HY, Mattay VS, Straub RE, Meyer-Lindenberg A, et al. FMRI evidence for functional epistasis between COMT and RGS4. Mol. Psychiatry. 2007;12(10):893–895
  7. Burdick KE, Lencz T, Funke B, Finn CT, Szeszko PR, Kane JM, et al. Genetic variation in DTNBP1 influences general cognitive ability. Hum. Mol. Genet. 2006;15(10):1563–1568
  8. Burdick KE, Goldberg TE, Funke B, Bates JA, Lencz T, Kucherlapati R, et al. DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr. Res. 2007;89(1–3):169–172
  9. Castner SA, Williams GV. Tuning the engine of cognition: a focus on NMDA/D1 receptor interactions in prefrontal cortex. Brain Cogn. 2007;63(2):94–122
  10. Donohoe G, Morris DW, Clarke S, McGhee KA, Schwaiger S, Nangle J-M, et al. Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study. Neuropsychologia. 2007;45(2):454–458
  11. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 2003;25(2):115–121
  12. Fallgatter AJ, Herrmann MJ, Hohoff C, Ehlis A-C, Jarczok TA, Freitag CM, et al. DTNBP1 (Dysbindin) gene variants modulate prefrontal brain function in healthy individuals. Neuropsychopharmacology. 2006;31(9):2002–2010
  13. Fangerau H, Ohlraun S, Granath RO, Nöthen MM, Rietschel M, Schulze TG. Computer-assisted phenotype characterisation for genetic research in psychiatry. Hum. Hered. 2004;58(3–4):122–130
  14. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for Axis I DSM-IV Disorders. New York: Biometrics Research; 1994;
  15. Funke B, Finn CT, Plocik AM, Lake S, DeRosse P, Kane JM, et al. Association of the DTNBP1 locus with schizophrenia in a US population. Am. J. Hum. Genet. 2004;75(5):891–898
  16. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science. 2002;296(5576):2225–2229
  17. Gold JM. Cognitive deficits are treatment targets in schizophrenia. Schizophr. Res. 2004;72(1):21–28
  18. Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr. Bull. 2007;33(5):1100–1119
  19. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry. 1996;153(3):321–330
  20. Hallmayer JF, Kalaydjieva l, Badcock J, Dragovic M, Howell S, Michie PT, et al. Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficits. Am. J. Hum. Genet. 2005;77(3):468–476
  21. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry. 2005;10(1):40–68
  22. Heinrichs RW. The primacy of cognition in schizophrenia. Am. Psychol. 2005;60(3):229–242
  23. Hoefgen B, Schulze TG, Ohlraun S, von Widdern O, Höfels S, Gross M, et al. The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol. Psychiatry. 2005;57(3):247–251
  24. Honea R, Verchinski BA, Pezawas L, Kolachana BS, Callicott JH, Mattay VS, et al. Impact of interacting functional variants in COMT on regional gray matter volume in human brain. Neuroimage. 2009;45(1):44–51
  25. Iizuka Y, Sei Y, Weinberger DR, Straub RE. Evidence that the BLOC-1 protein Dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J. Neurosci. 2007;27(45):12390–12395
  26. Joo E-J, Lee K-Y, Jeong SH, Ahn Y-M, Koo YJ, Kim YS. The Dysbindin gene (DTNBP1) and schizophrenia: no support for an association in the Korean population. Neurosci. Lett. 2006;407(2):101–106
  27. Kirov G, Ivanov D, Williams NM, Preece A, Nikolov I, Milev R, et al. Strong evidence for association between Dystrobrevin Binding Protein 1 Gene (DTNBP1) and schizophrenia in 488 parent–offspring trios from Bulgaria. Biol. Psychiatry. 2004;55(10):971–975
  28. Le Hellard S, Mühleisen TW, Djurovic S, Fernø J, Ouriaghi Z, Mattheisen M, et al. Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Mol. Psychiatry. 2008;Oct 21 [Electronic publication]
  29. Luciano M, Miyajima F, Lind PA, Bates TC, Horan M, Harris SE, et al. Variation in the Dysbindin gene and normal cognitive function in three independent population samples. Genes Brain Behav. 2009;8(2):218–227
  30. McGuffin P, Farmer AE, Harvey I. A polydiagnostic application of the operational criteria in studies of psychotic illness. Arch. Gen. Psychiatry. 1991;48(8):764–770
  31. Meisenzahl EM, Schmitt GJ, Scheuerecker J, Möller H-J. The role of dopamine for the pathophysiology of schizophrenia. Int. Rev. Psychiatry. 2007;19(4):337–345
  32. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215
  33. Morris DW, McGhee KA, Schwaiger S, Scully P, Quinn J, Meagher D, et al. No evidence for association of the Dysbindin gene (DTNBP1) with schizophrenia in an Irish population-based study. Schizophr. Res. 2003;60(2–3):167–172
  34. Mutsuddi M, Morris DW, Waggoner SG, Daly MJ, Scolnick EM, Sklar P. Analysis of high-resolution HapMap of DTNBP1 (Dysbindin) suggests no consistency between reported common variant associations and schizophrenia. Am. J. Hum. Genet. 2006;79(5):903–909
  35. Nicodemus KK, Kolachana BS, Vakkalanka R, Straub RE, Giegling I, Egan MF, et al. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum. Genet. 2007;120(6):889–906
  36. Peters K, Wiltshire S, Henders AK, Dragovicl M, Badcock JC, Chandler D, et al. Comprehensive analysis of tagging sequence variants in DTNBP1 shows no association with schizophrenia or with its composite neurocognitive endophenotypes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008;147B(7):1159–1166
  37. Posthuma D, Luciano M, de Geus EJC, Wright MJ, Slagboom PE, Montgomery GW, et al. A genome wide scan for intelligence identifies quantitative trait loci on 2q and 6p. Am. J. Hum. Genet. 2005;77(2):318–326
  38. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics. 2003;19(1):149–150
  39. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007;81(3):559–575
  40. Sanders AR, Duan J, Levinson DF, Shi J, He D, Hou C, et al. No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am. J. Psychiatry. 2008;165(4):497–506
  41. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, Dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet. 2003;72(1):185–190
  42. Sodhi M, Wood KH, Meador-Woodruff J. Role of glutamate in schizophrenia: integrating excitatory avenues of research. Expert Rev. Neurother. 2008;8(9):1389–1406
  43. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. second ed.. New York: Oxford Univerity Press; 1998;
  44. Straub RE, Jiang X, MacLean CJ, Ma Y, Webb BT, Myakishev MV, et al. Genetic variation in the 6p22.3 Gene DTNBP1, the human ortholog of the mouse Dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 2002;71(2):337–348
  45. Straub RE, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-Kerr C, et al. Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes. Mol. Psychiatry. 2002;7(6):542–559
  46. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, et al. Dysbindin is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J. Clin. Invest. 2004;113(9):1353–1363
  47. Tan HY, Chen Q, Sust S, Buckholtz JW, Meyers JD, Egan MF, et al. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc. Natl Acad. Sci. USA. 2007;104(30):12536–12541
  48. Treutlein J, Mühleisen TW, Frank J, Mattheisen M, Herms S, Ludwig KU, et al. Dissection of phenotype reveals possible association between schizophrenia and Glutamate Receptor Delta 1 (GRID1) gene promoter. Schizophr. Res. 2009;111(1–3):123–130
  49. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-O-methyltransferase, cognition and psychosis: Val158Met and beyond. Biol. Psychiatry. 2006;60(2):141–151
  50. Turunen JA, Peltonen JO, Pietiläinen OPH, Hennah W, Loukola A, Paunio T, et al. The role of DTNBP1, NRG1, and AKT1 in the genetics of schizophrenia in Finland. Schizophr. Res. 2007;91(1–3):27–36
  51. Van Den Bogaert A, Schumacher J, Schulze TG, Otte AC, Ohlraun S, Kovalenko S, et al. The DTNBP1 (Dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am. J. Hum. Genet. 2003;73(6):1438–1443
  52. Van den Oord EJCG, Sullivan PF, Jiang Y, Walsh D, O´Neill FA, Kendler KS, et al. Identification of a risk-haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families. Mol. Psychiatry. 2003;8(5):499–510
  53. Weikert CS, Straub RE, McClintock BW, Matsumoto M, Hashimoto R, Hyde TM, et al. Human Dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch. Gen. Psychiatry. 2004;61(6):544–555
  54. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 1990;39:19–52
  55. Williams NM, Preece A, Morris DW, Spurlock G, Bray NJ, Stephens M, et al. Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch. Gen. Psychiatry. 2004;61(4):336–344
  56. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004;27(11):683–690
  57. Zinkstok JR, de Wilde O, van Amelsvoort TAMJ, Tanck MW, Baas F, Linszen DH. Association between the DTNBP1 gene and intelligence: a case–control study in young patients with schizophrenia and related disorders and unaffected siblings. Behav. Brain Funct. 2007;3:19–28

PII: S0920-9964(09)00616-1

doi: 10.1016/j.schres.2009.12.025

Schizophrenia Research
Volume 118, Issue 1 , Pages 98-105 , May 2010

Article Tools

* Image Usage & Resolution